Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06438263 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 231
- Enrollment target
NCT06438263 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 231 participants.
The verdict
NCT06438263, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 231 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
Interventions
- DRUG Rocatinlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2025-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06438263
The ClinicalTrials.gov registry entry for NCT06438263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rocatinlimab is the first listed.
NCT06438263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06438263 about?
NCT06438263 is a clinical study titled "A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants". The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.
What is the current status of trial NCT06438263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 231 participants. The study started on 2024-08-06. Estimated completion is 2025-07-02.
What interventions are being tested in trial NCT06438263?
The interventions under investigation include: Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT06438263?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.